Randomised phase II trial of carboplatin and iproplatin in advanced urothelial cancer

• Published in: European journal of cancer (1990) Vol. 27; no. 11; p. 1383
• Main Authors: de Wit, R, Tesselaar, M, Kok, T C, Seynaeve, C, Rodenburg, C J, Verweij, J, Helle, P A, Stoter, G
• Format: Journal Article
• Language: English
• Published: England 01-01-1991
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Carboplatin - administration & dosage; Carboplatin - adverse effects; Carcinoma, Transitional Cell - drug therapy; Drug Evaluation; Female; Humans; Male; Middle Aged; Organoplatinum Compounds - administration & dosage; Organoplatinum Compounds - adverse effects; Random Allocation; Thrombocytopenia - chemically induced; Urinary Bladder Neoplasms - drug therapy; Vomiting - chemically induced
• ISSN: 0959-8049
• DOI: 10.1016/0277-5379(91)90015-6

47 patients with advanced urothelial cancer and no prior chemotherapy were randomly assigned to therapy with either carboplatin or iproplatin. Both platinum analogues were administered intravenously every 28 days at doses of 400 mg/m2 carboplatin and 300 mg/m2 iproplatin. None of 14 evaluable patients treated with carboplatin responded. Therefore, this arm was closed and from then on all eligible patients were registered on the iproplatin arm. 5 of 29 evaluable patients treated with iproplatin achieved a partial response (17%) for a median duration of 27 weeks (range 22-37). Iproplatin did not induce renal function disturbance. Gastrointestinal toxicity was mild to moderate. Bone marrow toxicity predominantly consisted of thrombocytopenia and required platelet transfusions in 13% of patients. 2 patients developed hypersensitivity reactions. It is concluded that the bone marrow toxicity and the chance of hypersensitivity render iproplatin an unattractive alternative to cisplatin.